Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 16.4% in December

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 12,800 shares, an increase of 16.4% from the November 30th total of 11,000 shares. Based on an average daily volume of 27,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.3% of the company’s stock are short sold.

Insider Buying and Selling

In related news, Director Marc Duey sold 6,462 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the completion of the transaction, the director now directly owns 233,651 shares of the company’s stock, valued at approximately $1,070,121.58. This represents a 2.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bernd R. Seizinger purchased 10,000 shares of the company’s stock in a transaction on Friday, October 11th. The stock was purchased at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the purchase, the director now directly owns 44,730 shares in the company, valued at approximately $119,876.40. This trade represents a 28.79 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 42,290 shares of company stock valued at $165,096. 12.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for about 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st largest position. Stonepine Capital Management LLC owned about 2.53% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a report on Tuesday, December 17th.

Aprea Therapeutics Price Performance

Shares of NASDAQ APRE opened at $3.29 on Wednesday. The business has a 50-day moving average of $3.40 and a 200-day moving average of $3.48. The stock has a market capitalization of $17.88 million, a price-to-earnings ratio of -1.17 and a beta of 0.88. Aprea Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.11. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.45 million. On average, sell-side analysts expect that Aprea Therapeutics will post -2.55 EPS for the current year.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.